Testing for prostate cancer – MiCheck® Prostate: quick, non-invasive, highly specific
MiCheck® Prostate is a blood test that uses our patented algorithm together with other biomarkers to estimate the risk of a patient having aggressive prostate cancer.
MiCheck® Prostate is designed to assist urologists in making the decision to recommend a patient for a biopsy or to recommend some form of active surveillance monitoring.
The problem in prostate cancer diagnosis
The PSA test is commonly used to detect prostate cancer however elevated PSA levels can be caused by factors other than prostate cancer.
Six men in ten with elevated PSA are needlessly subjected to an unnecessary prostate biopsy.
Prostate biopsies are invasive, unpleasant and sometimes hazardous (in relation to infection). This can make a man with elevated PSA reluctant to undergo a potentially unnecessary procedure. Additionally, prostate biopsies are expensive.
The estimated over-diagnosis using PSA for population screening in the USA (US Cancer Screening 2018) is 23-29% for Caucasian men and 35-44% for African-American men.
The solution for prostate cancer diagnosis is MiCheck® Prostate
MiCheck® Prostate can assist urologists in making the decision to refer a patient to biopsy by estimating the risk of the patient having aggressive prostate cancer. MiCheck® Prostate is a simple blood test that provides an answer to the physician on the patient’s cancer risk within 48 hours.
Examples of patient results
Why is MiCheck® Prostate the missing step in prostate cancer diagnosis?
- MiCheck® Prostate is more specific than a PSA test, and can help the urologist decide if a biopsy is really needed.
- Patients and their physicians will have confidence about what to do next. Patients with aggressive prostate cancer who should get treatment will get it sooner, and men whose MiCheck® Prostate results are negative can be monitored periodically instead of undergoing a prostate biopsy.